A new study suggests GLP-1 receptor agonists like Ozempic and Wegovy may significantly improve colon cancer survival rates. Researchers observed a lower five-year mortality among users, particularly those with high obesity, potentially due to reduced inflammation and improved metabolic health. While not proving direct anti-cancer effects, the findings highlight the interconnectedness of metabolic health and cancer biology.
